Showing 2971-2980 of 4166 results for "".
- Sydnexis Announces Three Abstracts Accepted for Poster Presentations at ARVOhttps://modernod.com/news/sydnexis-announces-three-abstracts-accepted-for-poster-presentations-at-arvo/2482780/Sydnexis announced that three abstracts have been accepted for poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 meeting taking place from May 4 to 8 in Salt Lake City. These posters present clinical data related to the STAR Study
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- Nanoscope Plans Phase 3 Trial of MCO-010 to Treat Stargardt Macular Degenerationhttps://modernod.com/news/nanoscope-plans-phase-3-trial-of-mco-010-to-treat-stargardt-macular-degeneration/2482440/Nanoscope Therapeutics announced the completion of an End-of-phase 2 (EOP2) meeting with the FDA for its clinical program evaluating MCO-010 for the treatment of severe vision loss caused by Stargardt macular degeneration (SMD), supporting advancement of MCO-010 to a phase 3 registrational trial.
- Atsena Therapeutics Publishes 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in LCA1https://modernod.com/news/atsena-therapeutics-publishes-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-lca1/2482431/Atsena Therapeutics announced 12-month safety and efficacy results from its phase 1/2 clinical trial of ATSN-101, an investigational gene therapy for Leber congenital amaurosis (LCA1), a rare inherited retinal disease causing severe vision impairment or blindness from infancy. The findi
- EyeCRO Presents Phase 2 Results for MiDROPS Platformhttps://modernod.com/news/eyecro-presents-phase-2-results-for-midrops-platform/2482276/EyeCRO has announced that data from the first clinical application of its MiDROPS (Microemulsion Drug Ocular Penetration System) platform technology was presented by Telios Pharma at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA. The presentation
- Nanoscope Announces Topline Results from Phase 2b Trial of MCO-010 for Retinitis Pigmentosahttps://modernod.com/news/nanoscope-announces-topline-results-from-randomized-phase-2b-trial-of-mco-010-for-retinitis-pigmentosa/2482183/Nanoscope Therapeutics announced positive topline results after the completion of the 2-year phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retini
- Kiora’s KIO-301 Molecular Photoswitch Evaluated for Retinitis Pigmentosa in ABACUShttps://modernod.com/news/kioras-kio-301-molecular-photoswitch-evaluated-for-retinitis-pigmentosa-in-abacus/2481946/Kiora Pharmaceuticals announced topline results of a phase 1/2 clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class intravitreal (IVT) molecular photoswitch, has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP)
- ChromaDex: Nicotinamide Riboside (NR) May be a Potential Therapeutic Strategy for Glaucoma Patientshttps://modernod.com/news/chromadex-nicotinamide-rrboside-nr-may-be-a-potential-therapeutic-strategy-for-glaucoma-patients/2481733/ChromaDex announced promising findings from two independent clinical study abstracts originally presented in April at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and recently published in the peer-reviewed ARVO journal, Investigativ
- Kiora: Investigational Drug KIO-301 Has Potential to Restore Light Perception in Patients with Retinitis Pigmentosahttps://modernod.com/news/kiora-investigational-drug-kio-301-has-potential-to-restore-light-perception-in-patients-with-retinitis-pigmentosa/2481574/Kiora Pharmaceuticals presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa. KIO-301 is a light-sensing small
- Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b Trial of Optogenetic Therapy for RPhttps://modernod.com/news/nanoscope-therapeutics-announces-positive-topline-results-from-phase-2b-trial-of-optogenetic-therapy-for-rp/2481504/Nanoscope Therapeutics announced topline results from the phase 2b RESTORE clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation. MCO-0